Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Arginine-Enriched Mixed-Charge Domains Provide Cohesion for Nuclear Speckle Condensation.

Greig JA, Nguyen TA, Lee M, Holehouse AS, Posey AE, Pappu RV, Jedd G.

Mol Cell. 2020 Feb 6. pii: S1097-2765(20)30046-0. doi: 10.1016/j.molcel.2020.01.025. [Epub ahead of print]

PMID:
32048997
2.

Formalin Versus Bouin Solution for Testis Biopsies: Which Is the Better Fixative?

Ellenburg JL, Kolettis P, Drwiega JC, Posey AM, Goldberg M, Mehrad M, Giannico G, Gordetsky J.

Clin Pathol. 2020 Jan 2;13:2632010X19897262. doi: 10.1177/2632010X19897262. eCollection 2020 Jan-Dec.

3.

Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell.

He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, Schreiber H.

JCI Insight. 2019 Dec 5;4(23). pii: 135306. doi: 10.1172/jci.insight.135306. No abstract available.

4.

Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies.

Schwab RD, Bedoya DM, King TR, Levine BL, Posey AD Jr.

Methods Mol Biol. 2020;2086:203-211. doi: 10.1007/978-1-0716-0146-4_15.

PMID:
31707678
5.

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells.

Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill S.

Blood. 2019 Nov 8. pii: blood.2019001859. doi: 10.1182/blood.2019001859. [Epub ahead of print]

PMID:
31703119
6.

Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell.

He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, Schreiber H.

JCI Insight. 2019 Nov 1;4(21). pii: 130416. doi: 10.1172/jci.insight.130416. Erratum in: JCI Insight. 2019 Dec 5;4(23):.

7.

Keeping the Engine Running: The Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development.

Migliorini D, Mason NJ, Posey AD.

ILAR J. 2018 Dec 31;59(3):276-285. doi: 10.1093/ilar/ilz009.

PMID:
31095687
8.

Engineering and Design of Chimeric Antigen Receptors.

Guedan S, Calderon H, Posey AD Jr, Maus MV.

Mol Ther Methods Clin Dev. 2018 Dec 31;12:145-156. doi: 10.1016/j.omtm.2018.12.009. eCollection 2019 Mar 15. Review.

9.

Phase Separation of Intrinsically Disordered Proteins.

Posey AE, Holehouse AS, Pappu RV.

Methods Enzymol. 2018;611:1-30. doi: 10.1016/bs.mie.2018.09.035. Epub 2018 Oct 31.

PMID:
30471685
10.

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology.

Watanabe K, Kuramitsu S, Posey AD Jr, June CH.

Front Immunol. 2018 Oct 26;9:2486. doi: 10.3389/fimmu.2018.02486. eCollection 2018. Review.

11.

Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.

Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, Cook DR, Thokala R, Blouch K, McGettigan-Croce B, Zhang L, Konradt C, Cogdill AP, Panjwani MK, Jiang S, Migliorini D, Dahmane N, Posey AD Jr, June CH, Mason NJ, Lin Z, O'Rourke DM, Johnson LA.

Mol Ther Oncolytics. 2018 Aug 28;11:20-38. doi: 10.1016/j.omto.2018.08.002. eCollection 2018 Dec 21.

12.

A First Glimpse of Nucleation of Phase Transitions in Living Cells.

Posey AE, Pappu RV.

Mol Cell. 2018 Jul 5;71(1):1-3. doi: 10.1016/j.molcel.2018.06.028.

13.

Driving cars to the clinic for solid tumors.

Castellarin M, Watanabe K, June CH, Kloss CC, Posey AD Jr.

Gene Ther. 2018 Jun;25(3):165-175. doi: 10.1038/s41434-018-0007-x. Epub 2018 Jun 7. Review.

PMID:
29880908
14.

Immunotherapy for Breast Cancer: Current and Future Strategies.

Williams AD, Payne KK, Posey AD Jr, Hill C, Conejo-Garcia J, June CH, Tchou J.

Curr Surg Rep. 2017 Dec;5. pii: 31. Epub 2017 Oct 10.

15.

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.

Wing A, Fajardo CA, Posey AD Jr, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S.

Cancer Immunol Res. 2018 May;6(5):605-616. doi: 10.1158/2326-6066.CIR-17-0314. Epub 2018 Mar 27.

16.

Inhibition of amyloid beta fibril formation by monomeric human transthyretin.

Garai K, Posey AE, Li X, Buxbaum JN, Pappu RV.

Protein Sci. 2018 Jul;27(7):1252-1261. doi: 10.1002/pro.3396. Epub 2018 Mar 14.

17.

Glycan-directed CAR-T cells.

Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey AD Jr.

Glycobiology. 2018 Sep 1;28(9):656-669. doi: 10.1093/glycob/cwy008. Review.

PMID:
29370379
18.

Profilin reduces aggregation and phase separation of huntingtin N-terminal fragments by preferentially binding to soluble monomers and oligomers.

Posey AE, Ruff KM, Harmon TS, Crick SL, Li A, Diamond MI, Pappu RV.

J Biol Chem. 2018 Mar 9;293(10):3734-3746. doi: 10.1074/jbc.RA117.000357. Epub 2018 Jan 22.

19.

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.

Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, Young RM, June CH.

JCI Insight. 2018 Jan 11;3(1). pii: 96976. doi: 10.1172/jci.insight.96976. eCollection 2018 Jan 11.

20.

Molecular Motor Dnm1 Synergistically Induces Membrane Curvature To Facilitate Mitochondrial Fission.

Lee MW, Lee EY, Lai GH, Kennedy NW, Posey AE, Xian W, Ferguson AL, Hill RB, Wong GCL.

ACS Cent Sci. 2017 Nov 22;3(11):1156-1167. doi: 10.1021/acscentsci.7b00338. Epub 2017 Nov 8.

Supplemental Content

Support Center